Cypress Bioscience Inc

Cypress Bioscience — Investor Presentation (September 2010)

20 slides from Cypress Bioscience's investor presentation, Sep 15, 2010

  1. Slide 1: Forward looking statements

    1 This presentation may contain certain forward-looking statements concerning the progress and development of the Company and its technology and products, including but not limited to its strategy, product candidates and programs, timelines and costs for their development, their potential therapeuti

  2. Slide 2: Overview

    Overview 2 Compelling opportunities in CNS market with large unmet needs; Potential economic impact is meaningful with good growth potential CNS is Cypress' historical strength; Rich history of CNS expertise, innovation and clinical development success Committed to delivering value to shareholders b

  3. Slide 3: CNS Today

    CNS Today CNS is a large market today CNS drugs generated $121B in worldwide sales in 2009* Large unmet needs in multiple areas 3 Several large pharmas are pulling out of or reducing their focus on CNS * NeuroInsights, The Neurotechnology Industry 2010 Report(tm)

  4. Slide 4: Overview

    Overview 4 Compelling opportunities in CNS market with large unmet needs; Potential economic impact is meaningful with good growth potential CNS is Cypress' historical strength; Rich history of CNS expertise, innovation and clinical development success Committed to delivering value to shareholders b

  5. Slide 5: Experience and Expertise

    Experience and Expertise Cypress' drug development team has deep expertise in psychiatry, neuropharmacology, and clinical trial methodology Combined 100+ years of clinical development experience Multiple approvals in devices (Prosorba(r)) and drugs (Savella(r)) Successful approvals and label expansi

  6. Slide 6: Overview

    Overview 6 Compelling opportunities in CNS market with large unmet needs; Potential economic impact is meaningful with good growth potential CNS is Cypress' historical strength; Rich history of CNS expertise, innovation and clinical development success Committed to delivering value to shareholders b

  7. Slide 7: Strategy: Renewed Focus on CNS Drug Development

    Strategy: Renewed Focus on CNS Drug Development Establish a leading portfolio of CNS assets, all of which will meet the following criteria: Address a large unmet clinical need and market opportunity Must be well-characterized, with primary residual risk being clinical/regulatory Must be innovative,

  8. Slide 8: Strategy: Renewed Focus on CNS Drug Development

    Strategy: Renewed Focus on CNS Drug Development Each of the new additions to our pipeline are high- quality, complementary opportunities to expand our reach in the CNS market: CYP-1020 - Cognitive impairment in schizophrenia Carbetocin - Social & repetitive behavior deficits in autism Staccato Nicot

  9. Slide 9: CYP-1020: Broad-Spectrum Antipsychotic Profile

    CYP-1020: Broad-Spectrum Antipsychotic Profile EAGLE P2B: Double blind, multi- center, 6-week study Full GCP trial conducted under U.S. FDA IND at 40 sites in the US, Europe and India 363 patients randomized as follows: BL-1020, 10mg/d BL-1020, 20-30mg/d Risperidone, 2-8mg/d Placebo Significant anti

  10. Slide 10: CYP-1020: Cognitive Impairment in Schizophrenia

    CYP-1020: Cognitive Impairment in Schizophrenia Unmet need - Cognitive deficits main predictor of long-term outcome, at least ~80% of patients with schizophrenia are affected Well-characterized - Robust P2b data in 363 patients, leveraging D2 antagonism and GABAergic activity Innovative - Potential

  11. Slide 11: Strategy: Renewed Focus on CNS Drug Development

    Strategy: Renewed Focus on CNS Drug Development Each of the new additions to our pipeline are high- quality, complementary opportunities to expand our reach in the CNS market: CYP-1020 - Cognitive impairment in schizophrenia Carbetocin - Social & repetitive behavior deficits in autism Staccato Nicot

  12. Slide 12: Carbetocin: Promising New Autism Therapy

    Carbetocin: Promising New Autism Therapy Carbetocin is a long-acting, synthetic, 8-amino acid, cyclic peptide analog of oxytocin Extensive preclinical data support the beneficial role of oxytocin in social behaviors, including pair bonding, social memory, etc. In acute studies in volunteers, intrana

  13. Slide 13: Carbetocin: Social Deficits in Autism

    Carbetocin: Social Deficits in Autism Unmet need - No approved therapies for the core social and repetitive behavior deficits Well-characterized - Carbetocin is a long-acting analog of the naturally occurring peptide, oxytocin Innovative - Carbetocin leverages the biology of naturally occurring horm

  14. Slide 14: Strategy: Renewed Focus on CNS Drug Development

    Strategy: Renewed Focus on CNS Drug Development Each of the new additions to our pipeline are high- quality, complementary opportunities to expand our reach in the CNS market: CYP-1020 - Cognitive impairment in schizophrenia Carbetocin - Social & repetitive behavior deficits in autism Staccato Nicot

  15. Slide 15: Staccato Nicotine: Unique Nicotine Replacement Therapy

    Staccato Nicotine: Unique Nicotine Replacement Therapy Staccato electronic multidose inhaler creates aerosolized nicotine, mimicking pK of smoked cigarette Enables tapering over time, plus rescue treatment of acute cravings 15

  16. Slide 16: Staccato Nicotine: Smoking Cessation

    Staccato Nicotine: Smoking Cessation Unmet need - The vast majority of smokers using existing nicotine replacement therapies (NRTs) relapse within 6 months Well-characterized - Nicotine is the addicting agent in cigarettes, but existing NRTs fail to mimic the pK of cigarettes, fail to control acute

  17. Slide 17: Deal terms for CYP-1020, Carbetocin and Staccato

    Covpress Biotinene cv -1020 (une 2010) Upfront 30M Deal Terms Estimated CYPBNearTerm Key Adltional Economic Rens, Tems *S1E0 Min Reg milestone ‘through approval *$85M Commercial Milestones *$s0M approval additional indications or other countries *cyP8 funds development S15Mtheough 2012 _* royalties

  18. Slide 18: We Have Financial Wherewithal to Execute on our Strategy

    18 We Have Financial Wherewithal to Execute on our Strategy Cash and short-term investment balance as of 30 June 2010: ~$105.5M Expect to end 2010 with ~$85M R&D burn for 2011 projected to be ~$16.5 million; baseline G&A cash burn expected to be in line with historic ~$10.5 million per year Shares o

  19. Slide 19: Moving Forward

    Moving Forward We will continue to actively seek out, acquire, and then develop innovative therapeutic candidates that meet the 4 strategic criteria, while maintaining financial discipline Compelling opportunities in CNS market with large unmet needs; Potential economic impact is meaningful with goo

  20. Slide 20: Investor Presentation September 2010

    Investor Presentation September 2010

Cypress Bioscience — Investor Presentation (September 2010) on 6ix